Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02899793|
Recruitment Status : Recruiting
First Posted : September 14, 2016
Last Update Posted : September 13, 2018
|Condition or disease||Intervention/treatment||Phase|
|Recurrent Endometrial Cancer||Drug: Pembrolizumab||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||25 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase II Evaluation of Pembrolizumab, a Humanized Antibody Against PD-1, in the Treatment of Persistent or Recurrent Hypermutated/Ultramutated Endometrial Cancer Identified by Next Generation Sequencing (NGS) and Comprehensive Genomic Profiling (CGP)|
|Study Start Date :||September 2016|
|Estimated Primary Completion Date :||December 2020|
|Estimated Study Completion Date :||December 2028|
Pembrolizumab 200 mg, Q3W, IV Infusion, Day 1 of each 3 week cycle
Pembrolizumab 200 mg (fixed dose) IV every 3 weeks (+/- 3 days) until progression or adverse effects prohibit therapy
Other Name: MK-3475
- Frequency of objective tumor response as assessed by RECIST 1.1 [ Time Frame: 24 months ]RECIST (Response Evaluation Criteria In Solid Tumors) is a set of published rules that define when cancer patients improve ("respond"), stay the same ("stable") or worsen ("progression") during treatments.
- Frequency and severity of adverse events as assessed by CTCAE v4 [ Time Frame: 24 months ]Common Terminology Criteria for Adverse Events (CTCAE) are a set of criteria for the standardized classification of adverse effects of drugs used in cancer therapy.
- Duration of progression-free survival (PFS) [ Time Frame: 24 months ]Progression-free survival is defined as the duration of time from study entry to time of progression, death, or the date of last contact, whichever occurs first.
- Overall survival (OS) [ Time Frame: 24 months ]Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02899793
|Contact: Alessandro D. Santin, M.D.||email@example.com|
|Contact: Lisa D. Baker, R.N.||firstname.lastname@example.org|
|United States, Connecticut|
|Yale New Haven Hospital||Recruiting|
|New Haven, Connecticut, United States, 06510|
|Contact: Alessandro D. Santin, M.D. 203-737-4450 email@example.com|
|Contact: Lisa Baker, R.N. 203-785-6398 firstname.lastname@example.org|
|Principal Investigator:||Alessandro D. Santin, M.D||Yale University|